The CERTH/CPERI review paper "Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis", doi:10.3390/brainsci10060333, by O. Kammona and C. Kiparissides, was selected for the cover of the scientific journal “Brain Sciences”.
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system and is considered to be the leading non-traumatic cause of neurological disability in young adults. The Holy Grail for the treatment of MS is to specifically suppress the disease while at the same time allow the immune system to be active against infections and malignancy. This could be achieved by developing immunotherapies designed to specifically suppress immune responses to myelin antigens.
The present paper attempts to highlight the various antigen-specific immunotherapies developed so far for the prevention/treatment of MS (e.g., vaccination with myelin-derived peptides/proteins, plasmid DNA encoding myelin epitopes, tolerogenic dendritic cells pulsed with encephalitogenic epitopes of myelin proteins, attenuated autologous T cells specific for myelin antigens, T cell receptor peptides, carriers loaded/conjugated with myelin immunodominant peptides, etc.), focusing on the outcome of their recent preclinical and clinical evaluation, and the challenges they face in order to be translated to MS patients. It also seeks to unravel the mechanisms involved in the immunopathogenesis and treatment of multiple sclerosis.